Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma

Documenti analoghi

• Real‐world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan
  di: Yuki Kita, et al.
  Pubblicazione: (2024)
• Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports
  di: Shintaro Mori, et al.
  Pubblicazione: (2024)
• Validation study on the 2 mm diameter cutoff in lymph node‐positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real‐world data analysis from a Japanese cohort
  di: Masashi Kato, et al.
  Pubblicazione: (2024)
• Deep early tumour shrinkage in metastatic upper tract urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab
  di: Marie Semmler, et al.
  Pubblicazione: (2026)
• Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real‐world data
  di: Koichi Uemura, et al.
  Pubblicazione: (2024)